Evidence map›Paper›PMID 39199676›Full record

ArticleCancers2024

Elevated GRHL2 Imparts Plasticity in ER-Positive Breast Cancer Cells.

Christy Zheng, Kaelyn O Allen, Tianrui Liu, Natalia M Solodin, Mark B Meyer, Kelley Salem, Phillipos K Tsourkas, Sean J McIlwain, Jessica M Vera, Erika R Cromwell and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Defining the DNA Binding Specificity of GRHL2.bioRxiv : the preprint server for biology · 2026
    Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Christy ZhengMcArdle Laboratory for Cancer Research, Department of Oncology, Carbone Comprehensive Cancer Center, University of Wisconsin-Madison, Madison, WI 53705, USA.
Kaelyn O AllenMcArdle Laboratory for Cancer Research, Department of Oncology, Carbone Comprehensive Cancer Center, University of Wisconsin-Madison, Madison, WI 53705, USA.
Tianrui LiuMcArdle Laboratory for Cancer Research, Department of Oncology, Carbone Comprehensive Cancer Center, University of Wisconsin-Madison, Madison, WI 53705, USA.
Natalia M SolodinMcArdle Laboratory for Cancer Research, Department of Oncology, Carbone Comprehensive Cancer Center, University of Wisconsin-Madison, Madison, WI 53705, USA.
Mark B MeyerDepartment of Nutritional Sciences, University of Wisconsin-Madison, Madison, WI 53706, USA.ORCID 0000-0001-6612-7491
Kelley SalemDepartment of Radiology, University of Wisconsin-Madison, Madison, WI 53792, USA.
Phillipos K TsourkasDepartment of Biostatistics and Medical Informatics, University of Wisconsin-Madison, Madison, WI 53705, USA.
Sean J McIlwainDepartment of Biostatistics and Medical Informatics, University of Wisconsin-Madison, Madison, WI 53705, USA.ORCID 0000-0002-3820-8400
Jessica M VeraDepartment of Biostatistics and Medical Informatics, University of Wisconsin-Madison, Madison, WI 53705, USA.
Erika R CromwellDepartment of Radiology, University of Wisconsin-Madison, Madison, WI 53792, USA.
Mary Szatkowski OzersMcArdle Laboratory for Cancer Research, Department of Oncology, Carbone Comprehensive Cancer Center, University of Wisconsin-Madison, Madison, WI 53705, USA.
Amy M FowlerDepartment of Radiology, University of Wisconsin-Madison, Madison, WI 53792, USA.ORCID 0000-0002-1172-1618
Elaine T AlaridMcArdle Laboratory for Cancer Research, Department of Oncology, Carbone Comprehensive Cancer Center, University of Wisconsin-Madison, Madison, WI 53705, USA.

Funding

UW COMPREHENSIVE CANCER CENTER SUPPORTP30CA014520 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI Justine Yang Bruce · 1985 to 2026
$142.6M
Mechanisms of Variant ER-alpha Function in Breast CancerR01CA260140 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI FOWLER, AMY · 2021 to 2025
$2.4M
Multi-color Benchtop Flow CytometerS10RR025483 · NCRR · UNIVERSITY OF WISCONSIN-MADISON · PI BUSHMAN, WADE A · 2009 to 2009
$449k
Automated Tissue MicroarrayerS10OD023526 · OD · UNIVERSITY OF WISCONSIN-MADISON · PI MATKOWSKYJ, KRISTINA A. · 2018 to 2018
$184k
NCI NIH HHS P30 CA014520NCI NIH HHS R01 CA260140NCRR NIH HHS S10 RR025483NIH HHS 5R01CA260140-04A1NIH HHS S10 OD023526
6 · The paper itself

Abstract

Estrogen receptor (ER)-positive breast cancer is characterized by late recurrences following initial treatment. The epithelial cell fate transcription factor Grainyhead-like protein 2 (GRHL2) is overexpressed in ER-positive breast cancers and is linked to poorer prognosis as compared to ER-negative breast cancers. To understand how GRHL2 contributes to progression, GRHL2 was overexpressed in ER-positive cells. We demonstrated that elevated GRHL2 imparts plasticity with stem cell- and dormancy-associated traits. RNA sequencing and immunocytochemistry revealed that high GRHL2 not only strengthens the epithelial identity but supports a hybrid epithelial to mesenchymal transition (EMT). Proliferation and tumor studies exhibited a decrease in growth and an upregulation of dormancy markers, such as

Indexed as

dormancyEMTepithelialhybrid EMTmesenchymalstemnesstumor progression

Identifiers

PMID39199676
PMCPMC11353109

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.